About Allstripes (formerly rdmd)
AllStripes (formerly RDMD) is a Public Benefit Corporation that is dedicated to unlocking new treatments for people affected by rare diseases. The company was founded in 2017 by Nancy Yu and Onno Faber, who both have personal experience with rare diseases. They recognized the need for a platform that could collect and analyze patient data to accelerate research and drug development.
AllStripes has developed a unique approach to collecting patient data. They partner with patient advocacy groups, hospitals, and clinics to gather medical records from patients with rare diseases. This data is then de-identified and analyzed using machine learning algorithms to identify patterns and potential treatment options.
The company's mission is driven by the fact that there are over 7,000 known rare diseases affecting over 400 million people worldwide. Many of these diseases have no approved treatments or cures, leaving patients without options or hope for improvement.
AllStripes aims to change this by providing researchers with access to high-quality patient data that can be used in drug development programs. By doing so, they hope to accelerate the discovery of new treatments for rare diseases.
One of the key benefits of AllStripes' approach is that it allows researchers to study smaller populations than traditional clinical trials would allow. This means that drugs can be developed specifically for patients with certain genetic mutations or other characteristics that are unique to their disease.
In addition, AllStripes' platform allows patients themselves to contribute directly to research efforts. Patients can opt-in to share their medical records and participate in surveys about their disease experience. This not only helps researchers better understand the disease but also empowers patients by giving them a voice in the research process.
AllStripes has already made significant progress towards its mission since its founding just a few years ago. The company has partnered with over 50 patient advocacy groups representing more than 500 different rare diseases. They have also worked with leading academic institutions such as Harvard Medical School and Stanford University on research projects.
Furthermore, AllStripes has raised $20 million in funding from investors who believe in their mission including Lux Capital, Spark Capital, Maverick Ventures, Two Sigma Ventures among others
Overall Allstripes (formerly RDMD) represents an innovative solution towards unlocking new treatments for people affected by rare disease through its unique approach towards collecting high-quality patient data which will help accelerate drug development programs while empowering patients themselves through direct participation into research efforts . With continued growth , partnerships ,and funding support ,the future looks bright as they continue making strides towards improving lives of millions around the world suffering from Rare Diseases .